Bris­tol My­ers touts up­beat da­ta for its block­buster heart drug can­di­date

While the FDA stretch­es out its re­view for Bris­tol My­ers Squibb’s mava­camten, the phar­ma gi­ant isn’t wast­ing any time bol­ster­ing en­thu­si­asm for the heart drug …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER